Zemdri approved to treat complicated urinary tract infections

June 28, 2018 9:22 AM | Anonymous

Monthly Prescribing Reference 

Achaogen announced that the U.S. Food and Drug Administration (FDA) has approved Zemdri (plazomicin) for adults (aged at least 18 years) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae. Zemdri, an aminoglycoside antibacterial, is a once-daily intravenous (IV) infusion that was designed to resist aminoglycoside-modifying enzymes.  

Read more.

Powered by Wild Apricot Membership Software